These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12543142)

  • 21. Genetic diversity of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax isolates from China.
    Wang S; Tian P; Li S; Liu H; Guo X; Huang F
    BMC Infect Dis; 2022 Dec; 22(1):944. PubMed ID: 36527077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Multi-Stage
    McCaffery JN; Fonseca JA; Singh B; Cabrera-Mora M; Bohannon C; Jacob J; Arévalo-Herrera M; Moreno A
    Front Cell Infect Microbiol; 2019; 9():135. PubMed ID: 31119106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limited sequence polymorphisms of four transmission-blocking vaccine candidate antigens in Plasmodium vivax Korean isolates.
    Kang JM; Ju HL; Moon SU; Cho PY; Bahk YY; Sohn WM; Park YK; Cha SH; Kim TS; Na BK
    Malar J; 2013 Apr; 12():144. PubMed ID: 23631662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequence polymorphisms of Plasmodium vivax ookinete surface proteins (Pvs25 and Pvs28) from clinical isolates in Korea.
    Han ET; Lee WJ; Sattabongkot J; Jang JW; Nam MH; An SS; Suh I; Lim CS
    Trop Med Int Health; 2010 Sep; 15(9):1072-6. PubMed ID: 20545923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Kohama H; Tachibana M; Matsuzaki G; Torii M; Arakawa T
    Infect Immun; 2010 Sep; 78(9):3773-82. PubMed ID: 20584978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.
    Arakawa T; Tsuboi T; Kishimoto A; Sattabongkot J; Suwanabun N; Rungruang T; Matsumoto Y; Tsuji N; Hisaeda H; Stowers A; Shimabukuro I; Sato Y; Torii M
    Vaccine; 2003 Jul; 21(23):3143-8. PubMed ID: 12804841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice.
    Kim TS; Kim HH; Moon SU; Lee SS; Shin EH; Oh CM; Kang YJ; Kim DK; Sohn Y; Kim H; Lee HW
    Exp Parasitol; 2011 Feb; 127(2):346-50. PubMed ID: 20801117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.
    Saul A; Hensmann M; Sattabongkot J; Collins WE; Barnwell JW; Langermans JA; Wu Y; Long CA; Dubovsky F; Thomas AW
    Parasite Immunol; 2007 Oct; 29(10):525-33. PubMed ID: 17883455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transmission-blocking vaccine candidate of Plasmodium vivax Pvs25 is highly conservative among Chinese isolates].
    Zheng L; Xu WM; Liu YJ; Yang YM; Cao YM
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Feb; 22(1):16-9. PubMed ID: 15283259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.
    Cao Y; Hayashi CTH; Kumar N
    J Infect Dis; 2024 Jun; 229(6):1894-1903. PubMed ID: 38408353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasmodium vivax malaria vaccine development.
    Arévalo-Herrera M; Herrera S
    Mol Immunol; 2001 Dec; 38(6):443-55. PubMed ID: 11741694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.
    Zhang Y; Liu F; Zhao Y; Yang F; Bai J; Jia X; Roobsoong W; Sattabongkot J; Cui L; Cao Y; Luo E; Wang M
    Parasit Vectors; 2021 Aug; 14(1):407. PubMed ID: 34399829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasmodium vivax ookinete surface protein (Pvs25) is highly conserved among field isolates from five different regions of the Brazilian Amazon.
    Chaves LB; Perce-da-Silva DS; Totino PRR; Riccio EKP; Baptista BO; de Souza ABL; Rodrigues-da-Silva RN; Machado RLD; de Souza RM; Daniel-Ribeiro CT; Banic DM; Pratt-Riccio LR; Lima-Junior JDC
    Infect Genet Evol; 2019 Sep; 73():287-294. PubMed ID: 31077839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Blagborough AM; Musiychuk K; Bi H; Jones RM; Chichester JA; Streatfield S; Sala KA; Zakutansky SE; Upton LM; Sinden RE; Brian I; Biswas S; Sattabonkot J; Yusibov V
    Vaccine; 2016 Jun; 34(28):3252-9. PubMed ID: 27177945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A two-dose viral-vectored
    Yamamoto Y; Fabbri C; Okuhara D; Takagi R; Kawabata Y; Katayama T; Iyori M; Hasyim AA; Sakamoto A; Mizukami H; Shida H; Lopes S; Yoshida S
    Front Immunol; 2024; 15():1372584. PubMed ID: 38745665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global genetic diversity of the Plasmodium vivax transmission-blocking vaccine candidate Pvs48/45.
    Vallejo AF; Martinez NL; Tobon A; Alger J; Lacerda MV; Kajava AV; Arévalo-Herrera M; Herrera S
    Malar J; 2016 Apr; 15():202. PubMed ID: 27067024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination.
    Duffy PE
    Expert Rev Vaccines; 2021 Feb; 20(2):185-198. PubMed ID: 33478283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy model for mosquito stage transmission blocking vaccines for malaria.
    Saul A
    Parasitology; 2008 Nov; 135(13):1497-506. PubMed ID: 18257944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restricted genetic heterogeneity of the Plasmodium vivax transmission-blocking vaccine (TBV) candidate Pvs48/45 in a low transmission setting: Implications for the Plasmodium vivax malaria vaccine development.
    Asali S; Raz A; Turki H; Mafakher L; Razmjou E; Solaymani-Mohammadi S
    Infect Genet Evol; 2021 Apr; 89():104710. PubMed ID: 33421653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.